Belching on Wegovy: What's Causing It and Whether It Will Pass

Why semaglutide makes your stomach gassy in the first place

Semaglutide acts on GLP-1 receptors in the gut and brain, and one of its direct effects in the stomach is to slow gastric emptying. Food and swallowed air that would normally move through quickly sit in the stomach for longer. That extended dwell time means more opportunity for gas to accumulate and for belching to be the body's way of clearing it. It is the same underlying process that causes other common GI complaints on the medicine, nausea, indigestion and a feeling of fullness that outlasts the meal itself.

A question our prescribers hear most weeks is whether belching means the dose is too high. Not necessarily. The gassy feeling is often strongest during the first few weeks at a new strength and then fades as the GI tract adjusts. The Wegovy treatment overview explains how the dose escalation schedule is designed partly with this tolerance window in mind. The NHS's patient information on semaglutide confirms that burping and indigestion are recognised side effects of semaglutide, sitting alongside nausea and diarrhoea in the same mild-to-moderate category.

It is also worth understanding that belching is not a sign the medicine is failing or doing harm. It is a predictable consequence of the pharmacology. That said, how much it disrupts daily life varies considerably from person to person, and that variability is a reason to keep your prescriber in the picture rather than trying to manage it entirely alone.

The practical factors that make belching better or worse

Because the stomach is already working slowly, anything that adds more air or prolongs the digestion process tends to amplify the problem. The most consistent culprits are eating too fast, drinking through straws, chewing gum and consuming carbonated drinks. Fizzy water feels virtuous but it is still fizzy: on Wegovy, even mild carbonation can tip a manageable amount of gas into a noticeably uncomfortable one.

Portion size matters too. One of the changes people notice on semaglutide is that the appetite signal cuts off sooner than it used to, but that does not always stop people eating the same volume out of habit. Overfilling a stomach that is already emptying slowly creates the conditions for both belching and nausea. Smaller, more frequent meals (chewed slowly and eaten at a table rather than on the go) tend to produce less bloating across the board. If you have been reading about the abdominal bloating some people notice on Wegovy, similar meal-pacing advice applies there.

Lying down within an hour or so of eating also makes it harder for gas to move through the system in the right direction. If evenings are when the belching tends to peak, it is often because the last meal of the day is the largest and sleep follows it too quickly. A short walk rather than the sofa after dinner is practical, not elaborate.

When belching is a signal to contact your prescriber rather than wait it out

Most belching on Wegovy is straightforward and self-limiting. There are circumstances, though, where it should prompt a call rather than patience. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known side effect of GLP-1 medicines, not common, but serious. The red flag symptom is severe, persistent stomach pain that spreads toward the back, which may or may not be accompanied by vomiting. Belching alongside pain of that character is not something to manage with dietary tweaks; it needs prompt medical assessment.

Persistent severe vomiting alongside belching matters too, because repeated vomiting can lead to dehydration quickly, and dehydration puts strain on the kidneys. If you cannot keep fluids down for more than a day, contact your prescriber or call 111. You can report unexpected side effects, including unusually severe digestive symptoms, via the MHRA Yellow Card scheme, which helps build the safety evidence base for all GLP-1 medicines.

There is a separate question some people ask once they are on treatment: does semaglutide affect appetite so strongly that they forget to eat altogether? The answer is that this does happen, and going too long without food then eating suddenly can trigger a wave of GI symptoms including belching. The guide on why some people feel they cannot eat on Wegovy covers that dynamic in more detail.

How to decide whether belching needs prescriber input or just a few adjustments

This is the practical frame that most people find useful. If the belching started in the first week at a new dose, is not getting worse and is not accompanied by pain, a few dietary changes and a fortnight's patience is reasonable. Slow down mealtimes, drop the sparkling water, cut portion sizes and avoid lying down straight after eating. Many people find that is enough.

If it has not improved after two to three weeks, or if it is affecting sleep, work or social situations, that is the point to contact your prescriber directly rather than keeping it to yourself. The treatment page at weight-loss-treatments explains how clinical review works at nume, and the frequently asked questions cover what happens between consultations. Aftercare is part of the service, not a separate step.

It is also worth checking whether any other digestive symptoms have appeared alongside the belching. Some people also notice skin reactions or other unexpected effects during GLP-1 treatment; the pages on itching on semaglutide and on eye twitching reported by some Wegovy users cover those questions separately. For broader context on what semaglutide is and how it differs from other medicines in the same class, the explainer on whether Wegovy and semaglutide are the same thing is a straightforward starting point.

If you are still deciding whether Wegovy is the right option for you, or want to understand how a clinical assessment works, checking your eligibility through a free consultation is the first step. A GPhC-registered prescriber reviews every application the same day, a real clinician, reading your answers.